Trends and Outcomes of Anticoagulation for Post‐Operative Atrial Fibrillation After Coronary Artery Bypass Graft
Pacing and Clinical Electrophysiology · 2025
DOI: 10.1111/pace.70069 ↗At a glance
Journal article in Pacing and Clinical Electrophysiology, 2025. Written by Daniel S Cheah and 4 co-authors. Institution: Carle Illinois College of Medicine, Urbana, Illinois, USA. Major MEDLINE topics: Atrial Fibrillation, Coronary Artery Bypass, Anticoagulants, Postoperative Complications. Cited 1 times so far (Crossref); 10 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background
The benefit of oral anticoagulation (OAC) in patients with new‐onset postoperative atrial fibrillation (POAF) after coronary bypass grafting remains uncertain. The 2023 American Heart Association (AHA) and the American College of Cardiology (ACC) guidelines recommend 60 days of anticoagulation for POAF, whereas management was previously left to the physician's discretion. The aim of this study is to identify the most effective anticoagulant regimens for reducing stroke rates in POAF patients after coronary artery bypass grafting (CABG).
Methods
Using the Epic Cosmos database, we included all US patients who underwent CABG without concomitant aortic/mitral valve replacement (MVR) from 2017 to 2023. Primary outcomes include demographics of POAF/non‐POAF patients and complication rates among patients without anticoagulation, on direct oral anticoagulation (DOAC), or on warfarin.
Results
Of the 147,546 patients studied, 7.6% (11,336) developed POAF. At 60 days, the use of OAC for POAF was associated with a decrease in all‐cause mortality without any difference in thromboembolism rates. At 12 months, there was no difference between all‐cause mortality and thromboembolism rates between the OAC and the no anticoagulation (NA) cohorts.
Conclusions
The benefit of long‐term anticoagulation of POAF following CABG with warfarin or DOAC remains unclear, as there was no reduction in thromboembolic events with anticoagulation despite a reduction in all‐cause mortality at 60 days. No significant reduction in thromboembolic events or all‐cause mortality was exhibited at 1 year. Thus, the benefit of long‐term anticoagulation of POAF following CABG with warfarin or DOAC remains unclear.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Carle Illinois College of Medicine, Urbana, Illinois, USA.
- Department of Cardiology, Carle Foundation Hospital, Urbana, Illinois, USA.
- Department of Medicine, West Virginia University, Morgantown, West Virginia, USA.
ORCID profiles: Kathryn Tsai
Cite
APA
Cheah, D. S., Tsai, K., Kurpad, K. P., Khalid, Y., & Mehta, S. S. (2025). Trends and Outcomes of Anticoagulation for Post‐Operative Atrial Fibrillation After Coronary Artery Bypass Graft. Pacing and Clinical Electrophysiology. https://doi.org/10.1111/pace.70069
Vancouver
Cheah DS, Tsai K, Kurpad KP, Khalid Y, Mehta SS. Trends and Outcomes of Anticoagulation for Post‐Operative Atrial Fibrillation After Coronary Artery Bypass Graft. Pacing and Clinical Electrophysiology. 2025. doi:10.1111/pace.70069
BibTeX
@article{Cheah2025,
author = {Cheah, Daniel S and Tsai, Kathryn and Kurpad, Krishna Prasad and Khalid, Yousra and Mehta, Sanjay S},
title = {Trends and Outcomes of Anticoagulation for Post‐Operative Atrial Fibrillation After Coronary Artery Bypass Graft},
journal = {Pacing and Clinical Electrophysiology},
year = {2025},
doi = {10.1111/pace.70069}
}
EUVIMED